scholarly journals Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

EBioMedicine ◽  
2022 ◽  
Vol 75 ◽  
pp. 103801
Author(s):  
Aleix Prat ◽  
Valentina Guarneri ◽  
Tomás Pascual ◽  
Fara Brasó-Maristany ◽  
Esther Sanfeliu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Survival Outcome ◽  
Pathological Response ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Development And Validation ◽  
Positive Breast Cancer

scholarly journals Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

2021 ◽  
Vol 22 (8) ◽  
pp. 1139-1150
Author(s):  
Rosie Bradley ◽  
Jeremy Braybrooke ◽  
Richard Gray ◽  
Robert Hills ◽  
Zulian Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Meta Analysis ◽  
Randomised Trials ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer

2019 ◽  
Vol 12 (4) ◽  
pp. 312-314 ◽  
Author(s):  
Christoph Suppan ◽  
Marija Balic
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Annual Meeting ◽  
Early Stage ◽  
Postoperative Treatment ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Adjuvant Breast Cancer ◽  
American Society ◽  
Positive Breast Cancer

Summary Early stage HER2-positive cancer outcomes have been substantially improved over the last two decades, but there is still some potential for improvement. Several studies on the preoperative/postoperative treatment of HER2-positive breast cancer were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting.

scholarly journals Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy

2013 ◽  
Vol 2013 ◽  
pp. 1-9 ◽  
Author(s):  
S. Guiu ◽  
M. A. Mouret Reynier ◽  
M. Toure ◽  
B. Coudert
Keyword(s):  
Breast Cancer ◽  
Response Rate ◽  
Neoadjuvant Treatment ◽  
Pathological Response ◽  
Complete Pathological Response ◽  
Her2 Positive ◽  
Major Step ◽  
Her2 Positive Breast Cancer ◽  
Made In ◽  
Positive Breast Cancer

Since 2005, major progresses have been made in the neoadjuvant treatment of HER2-positive breast cancer. Trastuzumab introduction associated with chemotherapy has been the first major step leading to the improvement of the complete pathological response rate and, like in the adjuvant studies, better survivals. Dual HER2 blockade has been the next step and trastuzumab is associated now with other anti-HER2 therapies like lapatinib or pertuzumab, the latter being much more easy to use in combination with chemotherapy. Additional knowledge is necessary to better define within the HER2 tumor subgroup which patients could benefit more from targeted therapies. Different biomarkers have been studied to predict the response after anti-HER2 neoadjuvant therapies but until now none has been validated.

Sign in / Sign up

Export Citation Format

Share Document